Despite attempts by the World Health Organization (WHO) to
stop the search for alternatives to combat COVID19, countries like the United
States and Russia continue to work to combat the pandemic.
Russia is disclosing that it has registered Koronavir, from
the company R-Pharm, the third drug to combat COVID-19 created on the basis of
the Japanese experimental flu vaccine favipiravir.
The country has previously registered two drugs: the first
was Avifavir, produced by the Russian Direct Investment Fund and the KhimRar
company, followed by Areplivir, from the Promomed company.
According to the information that the manufacturer of this
new drug is releasing, "It does not treat the complications produced by SARS-CoV-2,
but rather fights against the virus itself," which means a great advance
to end the pandemic.
Post a Comment
We want to know your comments and concerns. Remember: Respect distinguishes us, education makes us different...